查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2106251

全球誘導性多功能幹細胞（iPS細胞）市場：市場規模、趨勢與預測（2026年）

Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2026
出版日期: | 出版商: BioInformant | 英文 318 Pages | 訂單完成後即時交付

價格

自2006年誘導性多功能幹細胞（iPS細胞）技術發現以來，幹細胞生物學和再生醫學領域取得了顯著進展。新的疾病機制已被闡明，利用iPS細胞篩檢出的新藥正處於研發階段，並且正在進行利用人類iPS細胞衍生細胞類型的臨床試驗。 iPS細胞可用於闡明疾病發生和發展的原因，開發和檢驗新藥和療法，並治療以前被認為無法治癒的疾病。

目前，誘導性多功能幹細胞（iPS細胞）的商業化方法有多種，包括以下幾種：

  • 細胞療法：iPS 細胞正被研究用於各種細胞療法，旨在透過替換受損或失去的細胞來修復損傷和治癒疾病。
  • 疾病建模：透過將從患有特定疾病的患者身上獲得的 iPS 細胞分化為疾病特異性細胞類型，可以創建準確且功能性的「體外培養」疾病模型，用於研究和開發。
  • 藥物發現與新藥發現：iPS 細胞為藥物發現過程（如化合物鑑定、標靶檢驗、化合物篩檢和工具開發）提供生理相關的細胞，顯著提高了這些工作的效率和相關性。
  • 個人化醫療：透過將 iPS 細胞與 CRISPR 等基因組編輯技術結合，科學家可以引入精確的基因修飾，例如基因敲除、基因敲入或單鹼基替換，為根據個人基因譜量身定做的個人化療法鋪平道路。
  • 毒性測試：iPS 細胞或其衍生細胞（組織特異性細胞）用於毒性篩檢，以評估化合物和藥物在活細胞內的安全性和有效性，從而減少對動物試驗的依賴。
  • 組織工程：iPS 細胞可以在模擬目標組織結構和特徵的生物相容性支架上進行培養，提供支持細胞增殖和分化的環境，並有助於開發用於移植的工程組織。
  • 類器官建構：誘導多能幹細胞（iPS細胞）可以自組織成稱為「類器官」的3D結構，這些結構與人體器官的結構和功能高度相似。類器官在器官發育研究、疾病建模和候選藥物測試中發揮重要作用。
  • 基因編輯：利用CRISPR-Cas9等技術可以對iPS細胞進行改造，從而糾正致病突變或引入特定的基因修飾。這些經過編輯的iPS細胞隨後可以分化成功能性細胞，用於移植或深入的疾病研究。
  • 研究工具：iPS 細胞及其衍生物被廣泛用於基礎研究和應用研究，包括闡明細胞過程、了解疾病和檢驗實驗療法。
  • 幹細胞庫：iPS 細胞庫儲存並提供源自 iPS 細胞的各種細胞類型，為研究人員利用來自健康和患病捐贈者的細胞研究疾病提供了寶貴的資源。
  • 培養肉生產：iPS 細胞正被用於實驗室人造肉的生產，作為創造清潔、永續肉品的細胞基礎，而無需傳統的畜牧業。
  • 3D生物列印：iPS細胞可以分化成特定的細胞類型，如皮膚細胞、心肌細胞和肝細胞，透過將它們摻入生物墨水中並應用於3D生物列印，就可以創建複雜的組織結構。

iPS細胞市場的市場動態

自從大約20年前發現誘導多能幹細胞（iPS細胞）以來，該領域以前所未有的速度發展。 2013年，僅花了七年時間，首個源自iPS細胞的細胞產品就被移植到人體患者體內。此後，iPS細胞衍生的細胞在全球範圍內被擴大應用於臨床前試驗、醫生主導的研究和臨床試驗中，凸顯了其變革性的巨大潛力。

誘導多能幹細胞（iPS細胞）的發現徹底革新了多個科學領域，包括藥物研發、毒性測試和體外疾病建模，並對細胞和基因治療產生了重大影響。由於iPS細胞能夠在體外無限增殖並分化成特定細胞類型，因此它們是用途廣泛且理想的臨床細胞替代療法和高級疾病建模細胞來源。

首個利用誘導多能幹細胞（iPS細胞）的細胞療法於2013年在日本神戶理研中心啟動。這項由高橋正代博士主導的臨床試驗檢驗了iPS細胞衍生的視網膜細胞片在老齡化黃斑部病變患者的安全性。 2016年，Cynata Therapeutics公司獲得了CYP-001的臨床試驗批准，成為全球首例獲準用於治療類固醇抗藥性急性移植物抗宿主疾病（GvHD）的iPS細胞衍生的同種異體細胞製劑。此iPS細胞衍生的間質幹細胞（MSC）製劑在安全性和有效性方面均表現出良好的效果，並成功達到了其臨床終點。

目前，誘導多能幹細胞（iPS細胞）是至少228項正在進行的臨床試驗的核心，這些試驗針對多種疾病。 iPS細胞衍生的間質幹細胞（MSCs）正被用於治療類固醇抗藥性急性移植物抗宿主疾病（GvHD），而iPS細胞衍生的多巴胺前驅細胞則正在被評估用於治療帕金森氏症。在腫瘤學領域，iPS細胞衍生的自然殺手（iNK）細胞正被研究作為轉移性固體癌的癌症免疫療法。其他應用包括利用視網膜色素上皮細胞治療老齡化黃斑部病變（AMD），以及利用iPS細胞衍生的胰島素分泌BETA細胞治療第一型糖尿病。這些多樣化的治療項目凸顯了iPS細胞在治療多種疾病方面的巨大潛力。

在總合228項臨床試驗中，有66項專門評估iPS細胞衍生細胞作為治療藥物的療效，其餘試驗則不以治療為目的，例如用於疾病建模或研究。這些試驗主要集中於再生醫學領域，用於治療帕金森氏症、視網膜疾病、心臟衰竭和免疫系統疾病等，其中許多試驗處於I/II期臨床試驗階段。

近年來，iPS細胞領域併購活動持續活躍。其中包括Axol Biosciences收購Newcells Biotech和Phenocell，以及Century Therapeutics以3,500萬美元收購Clade 創業投資。此外，還出現了一系列旨在擴大符合GMP標準的生產能力並推廣現成異體細胞療法的策略聯盟和許可合作。創投依然強勁，預計在2023年至2026年4月期間將達到約10.4億美元。雖然這較2021年21.5億美元的尖峰時段有所下降，但投資人越來越青睞那些擁有自有全端生產平台、能夠從研發階段過渡到臨床治療階段的公司。

誘導多能幹細胞（iPS細胞）的商業性潛力也在顯著擴展。各公司正將iPS細胞衍生產品應用於藥物研發、疾病建模和毒性測試等領域。富士膠片細胞動力學國際公司（FCDI）是該領域的領導者之一。細胞動力學國際公司（CDI）由威斯康辛大學麥迪遜分校的詹姆斯湯姆森博士於2004年創立，並於2007年成為首批成功建立人類iPS細胞株的公司之一。 2015年，FUJIFILM以3.07億美元收購了CDI，成立了FCDI。如今，該公司已成為全球最大的用於科學研究和再生醫學的iPS細胞衍生人類細胞生產商。

ReproCELL成立於2009年，是東京大學和京都大學的衍生公司，也是第一個將誘導多能幹細胞（iPS細胞）產品商業化的公司。其iPS細胞衍生的心肌細胞系列產品「ReproCardio」為該產業的發展鋪平了道路。在歐洲，Evotec和Ncardia是領先的公司之一。總部位於德國漢堡的Evotec專注於利用iPS細胞進行藥物篩檢的產業化，並已建成全球最先進的iPS細胞平台之一。 Ncardia由Axiogenesis和Pluriomics於2017年合併而成，專注於將iPS細胞應用於心臟和神經系統。其前身Axiogenesis是首家於2010年獲得iPS細胞技術許可的歐洲公司。

大型科研用品公司在iPS細胞衍生產品的商業化過程中也扮演著至關重要的角色。這些公司包括Lonza、BD Biosciences、Thermo Fisher Scientific、Merck和Takara Bio等眾多企業。目前，共有90多家公司活躍於iPS細胞市場，為科學研究和治療應用提供廣泛的產品、服務和技術。

全球誘導性多能幹細胞（iPSC）市場持續快速成長。這份全面的報告概述了該領域的主要參與者、策略聯盟以及推動產業發展的創新成果。報告詳細介紹了iPSC研究、生產技術和臨床開發的現狀，重點關注iPSC相關的專利、出版物和臨床試驗，並說明了說明已知的利用iPSC衍生細胞的治療方案。此外，報告還涵蓋了資金籌措趨勢，檢驗了正在塑造市場未來的資金籌措活動、首次股票公開發行（IPO）以及共同開發契約。

本報告深入探討了誘導多能幹細胞（iPS細胞）在藥物研發中日益廣泛的應用，以及推動該領域成長的策略聯盟。報告按應用、技術、細胞類型和地區（北美、歐洲、亞太地區及世界其他地區）對市場規模進行了詳細分析。透過提供市場總規模數據和到2034年的預測成長率，報告展望了iPS細胞產業的未來。

憑藉其驚人的多功能性，誘導多能幹細胞（iPS細胞）有望重新定義醫學和生物技術的概念。從疾病建模和藥物研發到先進的細胞替代療法，iPS細胞正在各個層面推動創新。隨著企業不斷改進生產技術並拓展治療應用，iPS細胞的未來蘊藏著變革醫學和科學研究的巨大潛力。

關於出版商

我們的出版商是一家美國市場研究公司，成立於2006年，擁有近百萬的年線上讀者，在幹細胞市場追蹤領域擁有超過20年的經驗。身為首家也是唯一一家專注於幹細胞產業的市場研究公司，我們的研究成果曾被《日誌日報》和《Vogue》等知名刊物引用，並在托尼·羅賓斯的暢銷書《生命力》中有所提及。我們的出版商成立於2006年，總部位於華盛頓特區，位置優越，鄰近美國國立衛生研究院（NIH）、美國食品藥物管理局（FDA）、馬裡蘭生物技術走廊、國會決策者。除了擁有一支經驗豐富的分析師團隊外，我們的出版商還與全球誘導多能幹細胞（iPS細胞）市場的關鍵意見領袖（KOL）建立了無與倫比的進入許可權。

目錄

第1章：報告概要

第2章：引言

第3章：iPS細胞產業的現狀

  • 兩種利用誘導多能幹細胞的新療法首次獲得批准。
    • Amchepry（Lagune Procell）
    • ReHeart
  • 即將推出的iPSC衍生治療藥物
    • Fertilo
    • Bemdaneprocel（BRTX-100）
  • 目前正在進行臨床試驗的第二種iPSC衍生產品。
  • 利用iPSCs開發療法的臨床試驗現狀
  • 人工智慧驅動的iPSC製造業自動化
    • 提供人工智慧驅動自動化服務的公司
  • 目前正在使用的先進重編程技術
    • 主要的專利懸崖是
  • iPSC生產自動化轉型
  • iPSCs中基因組編輯工具的現狀
  • iPSC衍生疾病模型中類器官和3D組織的現狀
  • 參與企業數量顯著增加。
    • iPSC相關企業的類型

第4章 iPS細胞的生產

  • 組織採集和捐贈者篩檢
  • 體細胞分離與啟動
    • 真皮纖維母細胞的分離
  • 將體細胞再程式化為誘導性多能幹細胞
  • iPSC克隆的擴增與篩選
    • 再程式化後iPSC克隆的選擇
  • 誘導iPSCs分化為特定細胞類型
  • 利用誘導性多能幹細胞開發類器官
    • iPSC衍生類器官開發的關鍵步驟。

第5章：關於誘導性多功能幹細胞的研究論文

  • PubMed.gov 上與 iPSC 相關的論文數量迅速增加
  • iPSC 研究主題類別
    • PubMed上發表的關於iPSCs的病理學研究論文
    • 一篇發表在PubMed上的關於iPSC再程式化研究的論文
    • 一篇發表在PubMed上的關於iPSC分化研究的論文
    • 一篇發表在PubMed上的關於利用iPSCs進行藥物發現的論文
    • 一篇發表在PubMed上的關於利用iPSCs進行細胞治療的論文
    • iPSC研究的未來趨勢

第6章 iPS 細胞專利趨勢

  • 按司法管轄區分類的iPSC專利申請數量
  • iPSC專利申請人
  • iPSC專利申請的發明人
  • 主要iPSC專利擁有者
  • iPSC專利的當前法律地位
  • 近期iPSC專利授權活動
  • iPSC專利活動的未來成長方向

第7章 臨床試驗現況：誘導性多功能幹細胞

  • 後期iPSC臨床試驗及其進展
  • 目前招募狀態
  • 依研究設計進行的iPSC臨床試驗
  • 用於治療和非治療目的的iPSC臨床試驗
    • 利用iPSCs進行非治療性臨床研究（透過申請）
    • 治療研究中的目標疾病
    • 針對眼科疾病的iPSC臨床試驗
    • 臨床試驗：基於誘導性多能幹細胞（iPSC）的針對中樞神經系統疾病的臨床試驗
    • 誘導多能幹細胞衍生心肌細胞和肌肉產品的臨床試驗
    • 誘導性多能幹細胞在免疫療法和血液製品臨床試驗的應用
    • 臨床試驗中的間質藥物
  • 利用iPSCs進行不同研究階段的臨床試驗
  • 按資助者類型分類的iPSC臨床試驗
  • iPSC臨床試驗的地理分佈
  • 利用iPSCs預測臨床試驗的未來方向

第8章：iPS細胞領域的併購、合作與資金籌措活動

  • iPSC領域的併購
    • Axol Biosciences 收購 Newcells Biotech。
    • Axol Biosciences 收購 Phenocell。
    • Century Therapeutics 收購 Clade Therapeutics。
  • iPSC領域的夥伴關係/夥伴關係和授權協議
    • Cartherics & Catalent
    • Applied StemCell, Inc. & Cellipont Bioservices
    • GelMEDIX & Catalent
    • ISCT & JSRM
    • SmartCella Holding & Catalent
    • Mytos & Pluristyx
    • Cell X Technologies & BioLamina
    • Pluristyx & Solesis
    • Pluristyx & BioLamia
    • Celaid Therapeutics & AGC
    • Cellino & Karis Bio
    • Ginkgo Bioworks & Universal Cells
    • BrightPath Bio & Cellistic
    • Alloy Therapeutics & Takeda
    • Factor Bioscience & Eterna Therapeutics
    • Aspen Neuroscience & Cell X Technologies
    • Shinobi Therapeutics & Panasonic
    • SCG Cell Therapy and A*STAR
    • Charles River Laboratories & Pluristyx
    • Pluristyx & National Resilience, Inc
    • University of Texas & GeneCure
    • BlueRock Therapeutics &Bit.bio
    • 應用幹細胞公司與加州再生醫學研究所
  • iPSC領域的創業投資
    • Trailhead Biosystems, Inc.
    • Morphocell Technologies, Inc.
    • Aspen Neuroscience, Inc.
    • Celaid Therapeutics, Inc.
    • GC Therapeutics, Inc.
    • iRegene Therapeutics
    • Gameto
    • Pluristyx
    • Asgard Therapeutics
    • Kenai Therapeutics
    • Pluristyx
    • Fujifilm Cellular Dynamics
    • Mogrify, Ltd.
    • Heartseed, Inc.
    • Elevate Bio

第9章：誘導性多功能幹細胞（iPS細胞）的生成

  • 再程式化因子（OSKM 混合物/山中因子）
  • 直接重編程
  • 重編程因子的輸送
  • 基因組編輯技術在iPSC生成的應用
  • 誘導多能幹細胞衍生類器官的構建
  • 利用iPSC衍生心臟組織片進行開發
  • 開發iPSC衍生的RPE片層
  • EBiSC
  • RIKEN BRC
  • CiRA
  • Wicell
  • HipSci
  • hPSCreg
  • inStem
  • Coriell Institute for Medical Research
  • 非營利銀行和商業供應商之間iPSC生產線的成本差異
  • iPSC庫中的細胞來源和再程式化方法
  • iPSC 銀行的所有權和資金籌措
  • iPS細胞在基礎研究的應用
  • iPSCs在藥物研發的應用
  • 基於iPSC的產品和服務的成本
  • 全球區域多功能細胞（iPSCs）市場
  • 全球iPS細胞市場依市場區隔分類
  • 基於iPSC的再程式化技術的全球市場
  • 全球iPSC衍生細胞市場
  • 全球手動和自動iPSC生產服務市場
  • iPSC市場促進因素
  • iPSC市場限制因素
  • iPSC市場預測變化
  • 28bio
  • AcceGen
  • Accellta, Ltd
  • Alder Therapeutics
  • Aldevron
  • Allele Biotechnology
  • Altos Labs
  • Applied StemCell, Inc.（ASC）
  • Arktus Therapeutics, Co., Ltd
  • Aspen Neuroscience
  • ATCC
  • Axxam SpA
  • Axol Bioscience
  • BD Biosciences
  • Bit.bio
  • BlueRock Therapeutics
  • BPS Bioscience
  • BrainXell
  • BrainZell
  • BrightPath Biotherapeutics Co., Ltd.
  • Cartherics Pty Ltd
  • Catalent, Inc
  • Celogics
  • Celregen Therapeutics
  • Cellectis
  • CellGenix GmbH
  • Cellistic
  • CellSystems GmbH
  • Cellusion, Inc
  • Celregen Therapeutics
  • Century Therapeutics
  • Citius Pharmaceuticals, Inc
  • clock.bio
  • Creative Medical Technology Holdings, Inc
  • CUORiPS, Inc
  • Curi Bio, Inc
  • Cynata Therapeutics
  • CytoMed Therapeutics Limited
  • Defined Bioscience, Inc.
  • Editas Medicine
  • EditCo Bio, Inc.
  • ErneXa Therapeutics
  • Esco Lifesciences
  • Evotec
  • Eyestem Research Pvt. Ltd
  • Factor Biosynthesis, Inc
  • Fate Therapeutics, Inc
  • FUJIFILM Cellular Dynamics
  • Gameto, Inc.
  • GC Therapeutics
  • GenScript
  • GOLIVER THERAPEUTICS
  • Greenstone Biosciences
  • Healios KK
  • HeartBeat.bio AG
  • Heartseed, Inc.
  • Hebecell Corporation
  • HELP Therapeutics
  • Herophilus
  • Hesperos, Inc
  • Horizon Discovery
  • HUB Organoids BV
  • iCamuno Biotherapeutics
  • iHeart Japan Corporation
  • IN8Bio
  • InSphero
  • iPeace, Inc.
  • iPS Academia Japan, Inc
  • IPS HEART
  • iPSirius
  • iRegene Therapeutics
  • iXCells Biotechnologies
  • iXgene, Inc.
  • Jacobio Pharmaceuticals
  • Kangstem Biotech
  • Kenai Therapeutics
  • Khloris Biosciences, Inc.
  • Kiji Therapeutics
  • Lambda Biologics GmbH
  • Laverock Therapeutics
  • Lineage Cell Therapeutics
  • Lonza
  • Megakaryon Corporation
  • Miltenyi Biotec, Inc.
  • Morphocell Technologies, Inc
  • Myoridge Co. Ltd
  • Ncardia
  • NeuCyte, Inc
  • Neukio Biotherapeutics
  • NEXEL
  • Okomera
  • Organovo Holdings, Inc.
  • Orizuru Therapeutics
  • Oxford StemTech
  • Parallel Bio
  • Pixl Bio, Ltd.
  • Pluristyx, Inc
  • Porosome Therapeutics, Inc
  • Quell Therapeutics Ltd
  • Racthera Co., Ltd
  • Rege Nephro, Co., Ltd
  • Repairon GmbH
  • ReproCELL
  • Res Nova Biologics
  • Ricoh Biosciences, Inc.
  • Sampled
  • Sana Biotechnology
  • Sarcio, Inc.
  • SCG Cell Therapy, Pte. Ltd.
  • SereNeuro Therapeutics
  • Shinobi Therapeutics
  • STEMCELL Technologies
  • StemCardia
  • StemSight
  • Stemson Therapeutics
  • Stimuliver
  • Sumitomo Pharma
  • Synthego
  • Telescope Therapeutics
  • Tempo Bioscience
  • Tenaya Therapeutics
  • TGD Life Company Limited
  • Thermo Fisher Scientific Inc
  • Tolerance Bio
  • Trailhead Biosystems (R)
  • TreeFrog Therapeutics
  • Vanqua Bio
  • Vascugen, Inc
  • VCCT Inc
  • Vertex Pharmaceuticals
  • Vivodyne
  • Yashraj Biotechnology, Ltd

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been undertaken. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

  • Cellular Therapy: iPSCs are being investigated for use in a wide range of cell therapy applications aimed at reversing injuries or curing diseases by replacing damaged or lost cells.
  • Disease Modeling: iPSCs derived from patients with specific disorders can be differentiated into disease-specific cell types, enabling the creation of accurate, functional disease models "in a dish" for research and therapeutic development.
  • Drug Development and Discovery: iPSCs provide physiologically relevant cells for drug discovery processes, including compound identification, target validation, compound screening, and tool development, significantly improving the efficiency and relevance of these efforts.
  • Personalized Medicine: By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, paving the way for customized treatments tailored to individual genetic profiles.
  • Toxicology Testing: iPSCs or their derivatives (tissue-specific cells) are used for toxicology screening to assess the safety and efficacy of compounds or drugs in living cells, reducing reliance on animal testing.
  • Tissue Engineering: iPSCs can be cultured on biocompatible scaffolds that mimic the structure and properties of target tissues, providing a supportive environment for cell growth and differentiation and aiding the development of engineered tissues for transplantation.
  • Organoid Production: iPSCs can self-organize into 3D structures called organoids, which closely resemble the structure and function of human organs. Organoids are valuable for studying organ development, modeling diseases, and testing drug candidates.
  • Gene Editing: iPSCs can be modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic alterations. These edited iPSCs can then be differentiated into functional cells for transplantation or advanced disease studies.
  • Research Tools: iPSCs and their derivatives are extensively used in both basic and applied research to study cellular processes, understand diseases, and test experimental therapies.
  • Stem Cell Banking: iPSC repositories store and provide access to diverse iPSC-derived cell types, offering researchers valuable resources to investigate conditions using cells from both healthy and affected donors.
  • Cultured Meat Production: iPSCs are utilized in lab-grown meat production, serving as a cellular foundation for creating clean, sustainable meat products without the need for traditional animal farming.
  • 3D Bioprinting: iPSCs can be differentiated into specific cell types, such as skin, heart, or liver cells, and incorporated into bioinks for use in 3D bioprinting applications, enabling the creation of complex tissue structures.

iPSC Market Dynamics

Since the discovery of iPSCs approximately 20 years ago, the field has advanced at an unprecedented pace. It took just seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been increasingly used in preclinical studies, physician-led research, and clinical trials worldwide, underscoring their transformative potential.

The discovery of iPSCs has revolutionized several scientific fields, including drug discovery, toxicity testing, and in-a-dish disease modeling, while also having a profound impact on cell and gene therapy. Their ability to multiply indefinitely in vitro and differentiate into specialized cells has made them a highly versatile and ideal source for clinical cell replacement therapies and advanced disease modeling.

The first cellular therapy involving iPSCs began in 2013 at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, this trial investigated the safety of iPSC-derived retinal cell sheets in patients with macular degeneration. In 2016, Cynata Therapeutics achieved a world first by gaining approval for a clinical trial of an allogeneic iPSC-derived cell product, CYP-001, for treating steroid-resistant acute graft-versus-host disease (GvHD). This iPSC-derived mesenchymal stem cell (MSC) product demonstrated positive safety and efficacy results, successfully meeting its clinical endpoints.

Today, iPSCs are at the center of at least 228 ongoing clinical trials targeting a range of conditions. iPSC-derived MSCs are being tested for steroid-resistant acute GvHD, while dopaminergic progenitors derived from iPSCs are being evaluated for Parkinson’s disease. In oncology, iPSC-derived natural killer (iNK) cells are being studied as cancer immunotherapies for metastatic solid tumors. Other applications include the use of retinal pigment epithelial cells for age-related macular degeneration (AMD) and insulin-secreting beta cells derived from iPSCs for Type 1 diabetes. These diverse therapeutic programs highlight the vast potential of iPSCs in treating a variety of diseases.

Of the 228 total trials, 66 are specifically evaluating iPSC-derived cells as therapeutics - the rest are non-therapeutic, such as disease modeling a research use - with a focus on regenerative medicine applications like Parkinson's disease, retinal diseases, heart failure, and immune disorders, mostly in Phase I/II.

The iPS cell sector has seen steady M&A activity in recent years, including Axol Biosciences' acquisitions of Newcells Biotech and Phenocell, and Century Therapeutics' $35 million acquisition of Clade Therapeutics, alongside a wave of strategic partnerships and licensing deals aimed at scaling GMP-compliant manufacturing and advancing off-the-shelf allogeneic cell therapies. Venture capital investment has remained strong, totaling roughly $1.04 billion between 2023 and April 2026, down from a 2021 peak of $2.15 billion, as investors increasingly favor companies with proprietary, full-stack manufacturing platforms poised to move from research into clinical-stage therapeutics.

The commercial potential of iPSCs has also expanded significantly. Companies are leveraging iPSC-derived products in drug development, disease modeling, and toxicology testing. FUJIFILM Cellular Dynamics International (FCDI) stands out as one of the largest players in the field. Cellular Dynamics International (CDI), founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, became one of the first companies to derive human iPSC lines in 2007. In 2015, FUJIFILM acquired CDI for $307 million, creating FCDI, which is now the world’s largest producer of human cells derived from iPSCs for research and regenerative medicine.

ReproCELL, founded in 2009 as a venture from the University of Tokyo and Kyoto University, was the first company to commercialize iPSC products. Its ReproCardio line of iPSC-derived cardiomyocytes paved the way for the industry. In Europe, leading competitors include Evotec and Ncardia. Evotec, based in Hamburg, Germany, has built one of the most advanced iPSC platforms in the world, focusing on industrializing iPSC-based drug screening. Ncardia, formed through the merger of Axiogenesis and Pluriomics in 2017, specializes in cardiac and neural applications of iPSCs. Axiogenesis, one of its predecessors, was the first European company to license iPSC technology in 2010.

Large research supply companies are also playing a major role in the commercialization of iPSC-derived products. These include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and numerous others. Collectively, more than 90 companies are active in the iPSC market, offering a broad range of products, services, and technologies that cater to both research and therapeutic applications.

The global iPSC market continues to grow rapidly. A comprehensive report on the field provides an overview of key players, strategic partnerships, and innovations driving the sector. The report explores the current status of iPSC research, manufacturing technologies, and clinical developments. It highlights the rates of iPSC-related patents, publications, and trials, detailing all known therapeutic programs involving iPSC-derived cells. Additionally, the report covers the funding landscape, examining fundraising efforts, IPOs, and co-development agreements that are shaping the market’s trajectory.

The report also delves into the expanding use of iPSCs in drug discovery and the strategic partnerships that are driving growth in this sector. It presents a detailed breakdown of market size by application, technology, cell type, and geography (North America, Europe, Asia-Pacific, and the rest of the world). Total market size figures, along with projected growth rates through 2034, provide insights into the future of the iPSC industry.

With their remarkable versatility, iPSCs are set to redefine medicine and biotechnology. From disease modeling and drug discovery to advanced cell replacement therapies, iPSCs are driving innovation at every level. As companies continue to refine manufacturing technologies and expand therapeutic applications, the future of iPSCs holds immense promise for transforming healthcare and scientific research.

About the Publisher

With an online readership of nearly one million viewers per year, the publisher is a U.S. market research firm founded in 2006 that has over 20+ years of experience in tracking stem cell markets. As the first and only market research firm to specialize in the stem cell industry, the publisher’s research has been cited by the Wall Street Journal and Vogue Magazine, as well as quoted in Tony Robbin’s best-selling book, Life Force. Founded in 2006 and headquartered in Washington, DC, the publisher is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, the publisher has unparalleled access to key opinion leaders (KOLs) from across the global iPSC market.

Table of Contents

1. REPORT OVERVIEW

  • 1.1 Statement of the Report

2. INTRODUCTION

3. CURRENT STATUS OF IPSC INDUSTRY

  • 3.1 Approval of the First Two iPSC-based Therapies
    • 3.1.1 Amchepry (raguneprocel)
    • 3.1.2 ReHeart
  • 3.2 Forthcoming iPSC-Derived Therapeutics
    • 3.2.1 Fertilo
    • 3.2.2 Bemdaneprocel (BRTX-100)
  • 3.3 The Second Line of iPSC-based Products in Clinical Trials
  • 3.4 Current Status of iPSC-Based Clinical Trials for Therapeutic Development
  • 3.5 AI-Powered Automation in iPSC Manufacturing
    • 3.5.1 Companies Providing AI-Powered Automation Services
  • 3.6 Advanced Reprogramming Technologies Currently in use
    • 3.6.1 The Major Patent Cliff beginning in
      • 3.6.1.1 The New “Post-Expiry” Opportunities
  • 3.7 Shift toward Automation in iPSC Production
  • 3.8 Current Utilization of Genome-Editing Tools in iPSCs
  • 3.9 Current Utilization of Organoids & 3D Tissues in iPSC-Derived Disease Models
  • 3.10 Significant increase in the number of Market Participants
    • 3.10.1 Types of iPSC-Related Companies in
      • 3.10.1.1 The iPSC Therapeutics Developers (Clinical & Preclinical) Companies
      • 3.10.1.2 iPSC Product & Research Tool Suppliers
      • 3.10.1.3 Contract Development and Manufacturing Organizations (CDMOs)
      • 3.10.1.4 Longevity and Rejuvenation Companies (Partial Reprogramming)

4. IPSC MANUFACTURING

  • 4.1 Tissue Acquisition and Donor Screening
  • 4.2 Somatic Cell Isolation and Priming
    • 4.2.1 Isolation of Dermal Fibroblasts
  • 4.3 Reprogramming of Somatic Cells into iPSCs
  • 4.4 Expansion and Selection of iPSC Colonies
    • 4.4.1 Selection of iPSC Colonies after Reprogramming
  • 4.5 Directed Differentiation of iPSCs into Specific Cell Types
  • 4.6 Development of Organoids from iPSCs
    • 4.6.1 Key Steps in iPSC-Derived Organoid Development

5. RESEARCH PUBLICATIONS ON INDUCED PLURIPOTENT STEM CELLS

  • 5.1 Rapid Growth of iPSC Publications in PubMed.gov
  • 5.2 Categories of iPSC Research Themes
    • 5.2.1 PubMed Published iPSC Papers on Pathophysiological Studies
    • 5.2.2 PubMed Published iPSC Papers on Reprogramming Studies
    • 5.2.3 PubMed Published Papers on iPSC Differentiation Studies
    • 5.2.4 PubMed Published Papers on iPSC-based Drug Discovery
    • 5.2.5 PubMed Published Papers on iPSC-based Cell Therapy
    • 5.2.6 Future Trends in iPSC Research
      • 5.2.6.1 Anticipated advancements in Therapeutic Applications
      • 5.2.6.2 Enhanced Disease Modeling and Drug discovery
      • 5.2.6.3 Technological Innovations and Automation
      • 5.2.6.4 Future Research Directions and Challenges

6. IPSC PATENT LANDSCAPE

  • 6.1 iPSC Patent Applications by Jurisdiction
  • 6.2 iPSC Patent Applicants
  • 6.3 Inventors of iPSC Patent Applications
  • 6.4 Major iPSC Patent Owners
  • 6.5 Current Legal Status of iPSC Patents
    • 6.5.1 Granted iPSC Patents
    • 6.5.2 Key Technology Areas Protected
    • 6.5.3 Geographical Trends in iPSC Granted Patents
    • 6.5.4 Recently Granted iPSC Patents (2024-2026)
      • 6.5.4.1 Recent Patent of RxCell, Inc.
      • 6.5.4.2 Recent Patent of Pluristyx
      • 6.5.4.3 Recent Patent of Applied StemCell, Inc.
      • 6.5.4.4 Recent Patent of iPS Academia Japan/Kyoto University
      • 6.5.4.5 Recent Patent of Allele Biotechnology
  • 6.6 Recent iPSC Patent Licensing Activity
    • 6.6.1 Licensing Fees for iPSC Patents
  • 6.7 The Future Direction of Growth in iPSC Patent Activity
    • 6.7.1 The “Patent Cliff” and Focus Shift

7. CLINICAL TRIAL LANDSCAPE: INDUCED PLURIPOTENT STEM CELLS

  • 7.1 Late-Stage iPSC Clinical Trials & Progress
  • 7.2 Current Recruitment Status
  • 7.3 iPSC Clinical Trials by Study Designs
  • 7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials
    • 7.4.1 The iPSC Non-Therapeutic Clinical Studies by Use
    • 7.4.2 Diseases Targeted by Therapeutic Studies
    • 7.4.3 The iPSC Clinical Trials Addressing Ocular Diseases
    • 7.4.4 Trials IPSC-Based Clinical Trials Addressing CNS Disorders
    • 7.4.5 IPSC-Derived Cardiomyocytes and Muscle Products in Clinical Trials
    • 7.4.6 IPSC-Based in Immune and Blood Products Clinical Trials
    • 7.4.7 Stromal Products in Clinical Trials
  • 7.5 iPSC-based Clinical Trials by Phase of Study
  • 7.6 iPSC Clinical Trials by Funder Type
  • 7.7 Geographic Distribution of iPSC Clinical Trials
  • 7.8 Predicted Future Directions of iPSC-Based Clinical Trials

8. M&A, COLLABORATIONS AND FUNDING ACTIVITIES IN IPSC SECTOR

  • 8.1 Mergers and Acquisitions (M&A) in iPSC Sector
    • 8.1.1 Axol Biosciences’ Acquisition of Newcells Biotech
    • 8.1.2 Acquisition of Phenocell by Axol Biosciences
    • 8.1.3 Acquisition of Clade Therapeutics by Century Therapeutics
  • 8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector
    • 8.2.1 Cartherics & Catalent
    • 8.2.2 Applied StemCell, Inc. & Cellipont Bioservices
    • 8.2.3 GelMEDIX & Catalent
    • 8.2.4 ISCT & JSRM
    • 8.2.5 SmartCella Holding & Catalent
    • 8.2.6 Mytos & Pluristyx
    • 8.2.7 Cell X Technologies & BioLamina
    • 8.2.8 Pluristyx & Solesis
    • 8.2.9 Pluristyx & BioLamia
    • 8.2.10 Celaid Therapeutics & AGC
    • 8.2.11 Cellino & Karis Bio
    • 8.2.12 Ginkgo Bioworks & Universal Cells
    • 8.2.13 BrightPath Bio & Cellistic
    • 8.2.14 Alloy Therapeutics & Takeda
    • 8.2.15 Factor Bioscience & Eterna Therapeutics
    • 8.2.16 Aspen Neuroscience & Cell X Technologies
    • 8.2.17 Shinobi Therapeutics & Panasonic
    • 8.2.18 SCG Cell Therapy and A*STAR
    • 8.2.19 Charles River Laboratories & Pluristyx
    • 8.2.20 Pluristyx & National Resilience, Inc
    • 8.2.21 University of Texas & GeneCure
    • 8.2.22 BlueRock Therapeutics & Bit.bio
    • 8.2.23 Applied Stem Cell, Inc. & CIRM
  • 8.3 Venture Capital Funding in iPSC Sector
    • 8.3.1 Trailhead Biosystems, Inc.
    • 8.3.2 Morphocell Technologies, Inc.
    • 8.3.3 Aspen Neuroscience, Inc.
    • 8.3.4 Celaid Therapeutics, Inc.
    • 8.3.5 GC Therapeutics, Inc.
    • 8.3.6 iRegene Therapeutics
    • 8.3.7 Gameto
    • 8.3.8 Pluristyx
    • 8.3.9 Asgard Therapeutics
    • 8.3.10 Kenai Therapeutics
    • 8.3.11 Pluristyx
    • 8.3.12 Fujifilm Cellular Dynamics
    • 8.3.13 Mogrify, Ltd.
    • 8.3.14 Heartseed, Inc.
    • 8.3.15 Elevate Bio

9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

  • 9.1 Reprogramming Factors (OSKM Cocktail/Yamanaka Factors)
    • 9.1.1 Roles of OSKM Factors in the Induction of iPSCs
    • 9.1.2 Companies offering Reprogramming Services
  • 9.2 Direct Reprogramming
    • 9.2.1 Companies offering Direct Reprogramming Services
  • 9.3 Delivery of Reprogramming Factors
    • 9.3.1 Currently Favored Reprogramming Factors
      • 9.3.1.1 Sendai Virus (SeV) Reprogramming (Gold Standard)
      • 9.3.1.2 mRNA-Based Reprogramming (High Safety)
      • 9.3.1.3 Episomal Plasmid Vectors (Simplicity)
      • 9.3.1.4 Comparative Efficacies of Reprogramming Methods
  • 9.4 Genome Editing Technologies in iPSC Generation
    • 9.4.1 Companies offering CRISPR/Cas9 Services for iPSC Generation
  • 9.5 Development of iPSC-Derived Organoids
    • 9.5.1 Companies Developing iPSC-Derived Organoids
  • 9.6 Development of iPSC-Derived Cardiac Tissue Sheets
  • 9.7 Development of iPSC-Derived RPE Sheets
  • 10.1 EBiSC
    • 10.1.1 IPSCs Available with EBiSC
  • 10.2 RIKEN BRC
    • 10.2.1 The iPSC Lines available with RIKEN BRC
  • 10.3 CiRA
  • 10.4 WiCell
  • 10.5 HipSci
  • 10.6 hPSCreg
  • 10.7 inStem
  • 10.8 Coriell Institute for Medical Research
    • 10.8.1 Cell Lines offered by Coriell
  • 10.9 Cost Difference for iPSC Lines between Non-Profit Banks and Commercial Providers
  • 10.10 Cell Sources & Reprogramming Methods in iPSC Banks
  • 10.11 Ownership and Funding for iPSC Banks
  • 11.1 Applications of iPSCs in Basic Research
    • 11.1.1 Consumption of iPSC lines in Research
    • 11.1.2 Providers of iPSC Research Products for Researchers
    • 11.1.3 Product Categories used in iPSC Research
      • 11.1.3.1 The iPSC Reprogramming Kits
      • 11.1.3.2 Culture Media & Reagents used in Research
      • 11.1.3.3 Differentiated iPS Cells used in Research
      • 11.1.3.4 3D Organoids from iPSCs for Research
      • 11.1.3.5 Specialized Services in iPSC Manufacturing
      • 11.1.3.6 Procurement of iPSC-based Research Products by Researchers
        • 11.1.3.6.1 Procurement from Commercial Suppliers
        • 11.1.3.6.2 Procurement from Public and Private Repositories
        • 11.1.3.6.3 Direct Generation/Custom Services
  • 11.2 Applications of iPSCs in Drug Discovery
    • 11.2.1 Applications of iPSCs in Patient-Specific Disease Modeling
      • 11.2.1.1 Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery
        • 11.2.1.1.1 Drugs Tested for Cardiovascular Diseases using iPSCs
      • 11.2.1.2 Companies offering iPSC-derived Neuronal Cells for Drug Discovery
        • 11.2.1.2.1 Drugs Tested for Neurological Diseases using iPSCs
      • 11.2.1.3 Companies offering iPSC-Derived RPEs
        • 11.2.1.3.1 Drugs Tested for Ocular Diseases using iPSC Lines
      • 11.2.1.4 Companies developing iPSCs to Discover Drugs for Metabolic Diseases
        • 11.2.1.4.1 Drugs Tested in iPSCs for Metabolic Diseases
      • 11.2.1.5 Companies Developing iPSCs to Discover Drugs for Blood Disorders
        • 11.2.1.5.1 Drugs Tested for Blood Disorders using iPSCs
      • 11.2.1.6 The iPSCs in High-Throughput Screening (HTS)
      • 11.2.1.7 The iPSCs in Drug Toxicity and Safety Assessment
        • 11.2.1.7.1 Companies offering Toxicity Testing Services using iPSC-Derived Cells
        • 11.2.1.7.2 Drugs Tested for their Toxicity using iPSC Lines
        • 11.2.1.7.3 Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
      • 11.2.1.8 The iPSCs in Personalized Medicine and Genomic Studies
    • 11.2.3 Applications of iPSC-Derived Cells in Cell Therapies (Regenerative Medicine)
      • 11.2.3.1 Companies developing iPSC-based Cell Therapies
      • 11.2.3.2 The Landscape of iPSC-Based Cell Therapy Clinical Trials
        • 11.2.3.2.1 Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials
        • 11.2.3.2.2 iPSC-Based Cell Therapy Clinical Trials
    • 11.2.4 Other Novel Applications of iPSCs
      • 11.2.4.1 Bioinks for Tissue Engineering
        • 11.2.4.1.1 Companies developing iPSC-Based Bioinks
      • 11.2.4.2 The iPSCs in the Conservation of Endangered Species
        • 11.2.4.2.1 Key Applications of iPSCs Conservation
        • 11.2.4.2.2 Major Conservation Programs using iPSCs
        • 11.2.4.2.3 Development of iPSCs from Domestic & Wild Animals
      • 11.2.4.3 Cultured Meat Production using iPSCs
        • 11.2.4.3.1 Companies Developing Cultured Meat using iPSCs
  • 11.3 Cost of iPSC-Based Products & Services
  • 12.1 Global Market for Induced Pluripotent Stem Cells (iPSCs) by Geography
  • 12.2 Global Market for iPSCs by Market Segments
  • 12.3 Global Market for iPSC-based Reprogramming Technologies
  • 12.4 Global Market for iPSC-Derived Cell Types
  • 12.5 Global Market for Manual & Automated iPSC Production Services
    • 12.5.1 Market Share for Key Modules in iPSC Production
    • 12.5.2 Market Shares of Products Utilized in iPSC Manufacturing
    • 12.5.3 Percent Market Share of iPSC-Derived Cells by End-Use,
  • 12.6 Key iPSC Market Drivers
  • 12.7: Key iPSC Market Restraints
  • 12.8 Predicted Shifts in iPSC market
    • 12.8.1 Shift from Research to Clinical Applications
    • 12.8.2 Technological Shifts in Production and Quality
    • 12.8.3 Application & Therapeutic Shifts
    • 12.8.4 Regional & Strategic Shifts
  • 13.1 28bio
    • 13.1.1 The Nexon™ platform
    • 13.1.2 CNS-3D Technology
    • 13.1.3 CNS-3D Organoid Services
    • 13.1.4 PNS-3D Organoids
    • 13.1.5 PNS-3D Organoid Services
  • 13.2 AcceGen
    • 13.2.1 Treatments for Neurodegenerative Diseases with iPSCs
    • 13.2.2 AcceGen’s Pipeline
  • 13.3 Accellta, Ltd.
    • 13.3.1 Accellta’s Foodtech
    • 13.3.2 Accellta’s Biotech Services
    • 13.3.3 Accellta’s Core Technology
  • 13.4 Alder Therapeutics
  • 13.5 Aldevron
    • 13.5.1 Key Products and Services for iPSC
  • 13.6 Allele Biotechnology
    • 13.6.1 mRNA Reprogramming
    • 13.6.2 mRNA Differentiation
  • 13.7 Altos Labs
  • 13.8 Applied StemCell, Inc. (ASC)
    • 13.8.1 Genome Editing Platforms
    • 13.8.2 The iPSC Drug Discovery Platform
    • 13.8.3 The iPSC Gene Editing Services
    • 13.8.4 The iPSC Differentiation Services
    • 13.8.5 The iPSC Generation Services
    • 13.8.6 Product Offerings
  • 13.9 Arktus Therapeutics, Co., Ltd.
    • 13.9.1 Technologies
  • 13.10 Aspen Neuroscience
    • 13.10.1 Autologous Manufacturing Process
    • 13.10.2 Aspen’s Clinical Pipeline
  • 13.11 ATCC
    • 13.11.1 Product Offerings
  • 13.12 Axxam S.p.A.
    • 13.12.1 The iPSC Platform Capabilities
  • 13.13 Axol Bioscience
    • 13.13.1 Products
    • 13.13.2 Services
    • 13.13.3 iPSC-derived Models
  • 13.14 BD Biosciences
    • 13.14.1 Key Contributions and Tools
  • 13.15 Bit.bio
    • 13.15.1 Products & Services
      • 13.15.1.1 Human iPSC-derived glial cells
  • 13.16 BlueRock Therapeutics
    • 13.16.1 BlueRock’s Cell Therapy Programs
      • 13.16.1.1 Neurology Program
      • 13.16.1.2 Ophthalmology Program
  • 13.17 BPS Bioscience
    • 13.17.1 Product Offerings
  • 13.18 BrainXell
    • 13.18.1 Product Offerings
    • 13.18.2 Services Offered
  • 13.19 BrainZell
    • 13.19.1 Technology
    • 13.19.2 Selection of Source Cells
  • 13.20 BrightPath Biotherapeutics Co., Ltd.
  • 13.21 Cartherics Pty Ltd
    • 13.21.1 CTH-401
    • 13.21.2 CTH-004
  • 13.22 Catalent, Inc.
    • 13.22.1 Services
  • 13.23 Celogics
    • 13.23.1 Custom Cardiomyocytes
  • 13.24 Celregen Therapeutics
    • 13.24.1 Core Platform Technologies
    • 13.24.2 Key iPSC Product Candidates
  • 13.25 Cellectis
    • 13.25.1 TALEN® Technology
    • 13.25.2 PulseAgile Technology
  • 13.26 CellGenix GmbH
    • 13.26.1 Key Contributions
  • 13.27 Cellistic
    • 13.27.1 CDMO Services
    • 13.27.2 Allo Chassis™ Platform
    • 13.27.3 STAR-CRISPR™ Technology
    • 13.27.4 Pulse Cell Line Development Platform
    • 13.27.5 Cellistic’s Echo Manufacturing Platform
    • 13.27.6 GMP Manufacturing
    • 13.27.7 ECHO™-NK Platform
    • 13.27.8 Echo™-Cardio platform
    • 13.27.9 Echo™-Endothelial Platform
    • 13.27.10 Echo™-T Platform
  • 13.28 CellSystems GmbH
    • 13.28.1 Core Competencies in iPSC Technology
  • 13.29 Cellusion, Inc.
    • 13.29.1 CECSI Cells
  • 13.30 Celregen Therapeutics
    • 13.30.1 Products in Development
      • 13.30.1.1 Islet Cells
      • 13.30.1.2 The iCEnCs
  • 13.31 Century Therapeutics
    • 13.31.1 Century’s Approach
    • 13.31.2 Century’s Precision Gene Editing Technology
      • 13.31.2.1 Allo-Evasion™ Technology
    • 13.31.3 Century’s Pipeline Overview
  • 13.32 Citius Pharmaceuticals, Inc.
    • 13.32.1 Induced Mesenchymal Stem Cells (i-MSCs)
  • 13.33 clock.bio
    • 13.33.1 The clock.bio’s Platform
      • 13.33.1.1 The geneAge Atlas of Aging and Rejuvenation Genes
      • 13.33.1.2 The imAge
      • 13.33.1.3 The clinAge Platform
  • 13.34 Creative Medical Technology Holdings, Inc.
    • 13.34.1 The iPSCelz® Program
  • 13.35 CUORiPS, Inc
    • 13.35.1 Conditional Approval for ReHeart in Japan
      • 13.35.1.1 Treatment Modality for ReHeart
  • 13.36 Curi Bio, Inc.
    • 13.36.1 Curi Bio’s Biosystem Platforms
    • 13.36.2 3D Engineered Models
    • 13.36.3 The Curi Engine™: Custom Services
  • 13.37 Cynata Therapeutics
    • 13.37.1 Cymerus™ Technology
    • 13.37.2 Clinical Development
  • 13.38 CytoMed Therapeutics Limited
    • 13.38.1 iPSC-γδ NKT Cell Technology
  • 13.39 Defined Bioscience, Inc.
    • 13.39.1 Products for Disease Modeling
  • 13.40 Editas Medicine
    • 13.40.1 Edita’s iPSC Platform
  • 13.41 EditCo Bio, Inc.
    • 13.41.1 Services
    • 13.41.2 CRISPR Reagents & Kits
  • 13.42 ErneXa Therapeutics
  • 13.43 Esco Lifesciences
    • 13.43.1 Key Contributions
  • 13.44 Evotec
    • 13.44.1 Services
  • 13.45 Eyestem Research Pvt. Ltd.
    • 13.45.1 Eyecyte-RPE™
    • 13.45.2 Eyecyte-PRPTM
    • 13.45.3 AAV mediated gene augmentation
  • 13.46 Factor Biosynthesis, Inc.
    • 13.46.1 The mRNA Reprogramming Technology Platforms
    • 13.46.2 UltraSlice™ Gene Editing Technology Platforms
  • 13.47 Fate Therapeutics, Inc.
    • 13.47.1 Fate Therapeutics’ iPSCs Platform
    • 13.47.2 Fate Therapeutics’ Pipeline Overview
  • 13.48 FUJIFILM Cellular Dynamics
    • 13.48.1 Products
    • 13.48.2 Custom Services
    • 13.48.3 The iPSC CDMO Services
  • 13.49 Gameto, Inc.
    • 13.49.1 Gameto’s Science
      • 13.49.1.1 Fertilo
      • 13.49.1.2 Ameno
      • 13.49.1.3 Deovo
  • 13.50 GC Therapeutics
    • 13.50.1 TFome™ Platform
  • 13.51 GenScript
    • 13.51.1 iPSC-Related Services
    • 13.51.2 iPSC-Related Products
  • 13.52 GOLIVER THERAPEUTICS
    • 13.52.1 GOLIVER Solution
  • 13.53 Greenstone Biosciences
    • 13.53.1 Products
    • 13.53.2 Services
  • 13.54 Healios K.K.
  • 13.55 HeartBeat.bio AG
    • 13.55.1 Cardioids (Cardiac Organoids)
      • 13.55.1.1 Cardioid Drug Discovery Platform
    • 13.55.2 Disease Models
    • 13.55.3 Assays
    • 13.55.4 Drug Discovery Strategy
  • 13.56 Heartseed, Inc.
    • 13.56.1 Remuscularization Technology
    • 13.56.2 Cardiomyocyte Spheroid
  • 13.57 Hebecell Corporation
    • 13.57.1 ProtoNK™
    • 13.57.2 Contract Manufacturing Services
  • 13.58 HELP Therapeutics
  • 13.59 Herophilus
    • 13.59.1 Herophilus’ Approach
  • 13.60 Hesperos, Inc.
    • 13.60.1 Human-on-a-Chip®
  • 13.61 Horizon Discovery
  • 13.62 HUB Organoids BV
    • 13.62.1 Products
  • 13.63 iCamuno Biotherapeutics
    • 13.63.1 Transient Naive Treatment (TNT)
  • 13.64 iHeart Japan Corporation
    • 13.64.1 Contract Services
  • 13.65 IN8Bio
    • 13.65.1 INB-500
  • 13.66 InSphero
    • 13.66.1 Products & Services
  • 13.67 iPeace, Inc.
    • 13.67.1 Products
    • 13.67.2 Manufacturing Service
  • 13.68 iPS Academia Japan, Inc.
    • 13.68.1 Key Aspects of iPS Academia Japan, Inc.
  • 13.69 IPS HEART
    • 13.69.1 Proprietary Platform
      • 13.69.1.1 ISX9-CPC
      • 13.69.1.2 GIVI-MPC
  • 13.70 iPSirius
    • 13.70.1 iPVAC Technology
    • 13.70.2 iPSirius’ Pipeline
  • 13.71 iRegene Therapeutics
    • 13.71.1 iReDita Platform
  • 13.72 iXCells Biotechnologies
    • 13.72.1 iXCells’ Core Services
    • 13.72.2 Products
      • 13.72.2.1 Organoids
  • 13.73 iXgene, Inc.
    • 13.73.1 Technology
  • 13.74 Jacobio Pharmaceuticals
    • 13.74.1 Jacobio’s iPSC Collaboration with Hebecell
  • 13.75 Kangstem Biotech
  • 13.76 Kenai Therapeutics
    • 13.76.1 Kenai’s iPSC Platform
    • 13.76.2 Kenai’s Pipeline
  • 13.77 Khloris Biosciences, Inc.
  • 13.78 Kiji Therapeutics
  • 13.79 Lambda Biologics GmbH
    • 13.79.1 Organoid Services
  • 13.80 Laverock Therapeutics
    • 13.80.1 iPSC-derived Cell Therapies
  • 13.81 Lineage Cell Therapeutics
  • 13.82 Lonza
    • 13.82.1 Key Contributions
  • 13.83 Megakaryon Corporation
    • 13.83.1 Technology
    • 13.83.2 Megakaryons R&D Pipeline
  • 13.84 Miltenyi Biotec, Inc.
    • 13.84.1 Tools for Manual iPSC Workflows
    • 13.84.2 Automated and Closed iPSC Manufacturing
  • 13.85 Morphocell Technologies, Inc.
    • 13.85.1 ReLiver
  • 13.86 Myoridge Co. Ltd.
    • 13.86.1 Products & Services
  • 13.87 Ncardia
    • 13.87.1 Products
    • 13.87.2 Services
  • 13.88 NeuCyte, Inc.
    • 13.88.1 Technology
    • 13.88.2 NeuCyte’s Services
  • 13.89 Neukio Biotherapeutics
  • 13.90 NEXEL
    • 13.90.1 Organoids
    • 13.90.2 iPSC Derived Cells
    • 13.90.3 Instruments
    • 13.90.4 NeXST (Next Xight Screening Test)
    • 13.90.5 Disease Modeling
    • 13.90.6 Cell Customization
    • 13.90.7 Services
  • 13.91 Okomera
    • 13.91.1 Ocentra
  • 13.92 Organovo Holdings, Inc.
    • 13.92.1 Product Pipeline
  • 13.93 Orizuru Therapeutics
  • 13.94 Oxford StemTech
    • 13.94.1 Services Offered
  • 13.95 Parallel Bio
  • 13.96 Pixl Bio, Ltd.
    • 13.96.1 Platform
    • 13.96.2 Products
      • 13.96.2.1 The pixStellate iPSC-derived Stellate Cells
      • 13.96.2.2 pixHep/pixStellate Co-Culture Models
      • 13.96.2.3 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Models
      • 13.96.2.4 The pixHep A1ATD (Alpha-1 Antitrypsin Deficiency) Models
      • 13.96.2.5 The pixHep PFIC2 (Progressive Familial Intrahepatic Cholestasis Type 2) Model
      • 13.96.2.6 The pixHep UCD (Urea Cycle Disorder) Models (ASS1, and OTC)
  • 13.97 Pluristyx, Inc.
    • 13.97.1 FailSafe Cell System
    • 13.97.2 iACT Stealth Cells™
    • 13.97.3 Products
      • 13.97.3.1 PluriBank™
      • 13.97.3.2 PluriForm™ Kit
      • 13.97.3.3 PluriFreeze™ Cryopreservation System
      • 13.97.3.4 PluriKit™
    • 13.97.4 iPSC Generation
    • 13.97.5 Differentiated Cells
  • 13.98 Porosome Therapeutics, Inc.
    • 13.98.1 iPSC Derived Beta Cell T1D Therapy
  • 13.99 Quell Therapeutics Ltd
    • 13.99.1 Collaboration for iPSCs
  • 13.100 Racthera Co., Ltd.
    • 13.100.1 Amchepry®
    • 13.100.2 Racthera’s Retinal Sheet (DSP-3077)
    • 13.100.3 Racthera's Retinal pigment epithelial cells (HLCR011)
    • 13.100.4 Racthera's Neural progenitor cells (SMP-0115)
  • 13.101 Rege Nephro, Co., Ltd.
    • 13.101.1 RN-032
  • 13.102 Repairon GmbH
    • 13.102.1 Technology
  • 13.103 ReproCELL
    • 13.103.1 Services
    • 13.103.2 Product Offerings
    • 13.103.3 ReproCELL’s Clinical Pipelines
  • 13.104 Res Nova Biologics
  • 13.105 Ricoh Biosciences, Inc.
    • 13.105.1 Products
    • 13.105.2 Ricoh’s iPSC-related Services
    • 13.105.3 Ricoh’s Therapeutics Development Pipeline
  • 13.106 Sampled
    • 13.106.1 Services
  • 13.107 Sana Biotechnology
  • 13.108 Sarcio, Inc.
    • 13.108.1 SEV-101
    • 13.108.2 SEVA-101
  • 13.109 SCG Cell Therapy, Pte. Ltd.
  • 13.110 SereNeuro Therapeutics
  • 13.111 Shinobi Therapeutics
  • 13.112 STEMCELL Technologies
    • 13.112.1 Services
  • 13.113 StemCardia
    • 13.113.1 Core Product & Technology
  • 13.114 StemSight
    • 13.114.1 StemSight’s Technology
  • 13.115 Stemson Therapeutics
    • 13.115.1 KeyProduct & Service Portfolio
  • 13.116 Stimuliver
  • 13.117 Sumitomo Pharma
  • 13.118 Synthego
    • 13.118.1 Core Capabilities
  • 13.119 Telescope Therapeutics
    • 13.119.1 Core Cellular & Technology Platforms
  • 13.120 Tempo Bioscience
    • 13.120.1 Products
  • 13.121 Tenaya Therapeutics
    • 13.121.1 Drug Development Capability
    • 13.121.2 Disease Models
  • 13.122 TGD Life Company Limited
    • 13.122.1 R&D Services
  • 13.123 Thermo Fisher Scientific Inc.
    • 13.123.1 Key Contributions
  • 13.124 Tolerance Bio
  • 13.125 Trailhead Biosystems®
    • 13.125.1 HD-DoE (high-dimensional design-of-experiments) technology
    • 13.125.2 Trailhead’s Hematopoietic Progenitor Cells
    • 13.125.3 hiPSC-derived Dopaminergic Neurons
    • 13.125.4 hiPSC-derived Pancreatic Beta Cells
  • 13.126 TreeFrog Therapeutics
    • 13.126.1 C-Stem™
  • 13.127 Vanqua Bio
    • 13.127.1 Pipeline
  • 13.128 Vascugen, Inc.
    • 13.128.1 Core Technology & Approach
  • 13.129 VCCT Inc.
    • 13.129.1 VCCT’s Product Candidates
  • 13.130 Vertex Pharmaceuticals
    • 13.130.1 Key iPSC-Based Products & Programs
  • 13.131 Vivodyne
    • 13.131.1 Lab-Grown Organs
  • 13.132 Yashraj Biotechnology, Ltd.
    • 13.132.1 Products
      • 13.132.1.1 Induced Pluripotent Stem Cell (iPSC) Lines
      • 13.132.1.2 iPSC-Derived Cardiomyocytes (YBLiCardio)
      • 13.132.1.3 iPSC-Derived Hepatocytes Like Cells (YBLiHepato)

INDEX OF FIGURES

  • FIGURE 5.1: Rapid Growth of iPSC Publications in PubMed.gov
  • FIGURE 5.2: PubMed Published iPSC Papers on Pathophysiological Studies
  • FIGURE 5.3: PubMed Published iPSC Papers on Reprogramming Studies
  • FIGURE 5.4: PubMed Published Papers on iPSC Differentiation Studies
  • FIGURE 5.5: PubMed Published Papers on iPSC-based Drug Discovery
  • FIGURE 5.6: PubMed Published Papers on iPSC-based Cell Therapy
  • FIGURE 6.1: Number of iPSC Patents filed per Year, 2000-April 3, 2026
  • FIGURE 7.1: iPSC Clinical Trials by Study Designs
  • FIGURE 7.2: Therapeutic & Non-Therapeutic iPSC Clinical Trials
  • FIGURE 7.3: Non-Therapeutic iPSC Clinical Trials by Use
  • FIGURE 7.4: Percent Share of Diseases Targeted by Therapeutic Studies
  • FIGURE 7.5: iPSC Clinical Trials by Funder Type
  • FIGURE 7.6: Geographic Distribution of iPSC Clinical Trials
  • FIGURE 9.1: Roles of OSKM Factors in the Induction of iPSCs
  • FIGURE 9.2: Delivery Methods for Reprogramming Factors
  • FIGURE 11.1: Biomedical Applications of iPSCs
  • FIGURE 11.2: Potential of iPSCs in Toxicity Testing and Drug Screening
  • FIGURE 11.3: Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
  • FIGURE 12.1: Global Market for iPSCs by Geography, 2025-2034
  • FIGURE 12.2: Global Market for iPSCs by Market Segments
  • FIGURE 12.3: Global Market for iPSC-Related Reprogramming Technologies, 2026-2034
  • FIGURE 12.4: Global Market for iPSC-Derived Cell Types, 2025
  • FIGURE 12.5: Global Market for Manual & Automated iPSC Production Services, 2025
  • FIGURE 12.6: Market Share for Key Modules in iPSC Production, 2025
  • FIGURE 12.7: Market Shares of Products Utilized in iPSC Manufacturing, 2025
  • FIGURE 12.8: Percent Market Share of iPSC-Derived Cells by End-Use, 2025

INDEX OF TABLES

  • TABLE 3.1: Examples of iPSC-based Autologous & Allogeneic Products in Phase II
  • TABLE 3.2: Disease Areas Focused by iPSC-based Clinical Trials
  • TABLE 3.3: Companies Providing AI-Powered Automation Services
  • TABLE 3.4: Key Platforms used in Automatic iPSC Production
  • TABLE 4.1: Donor Selection and Screening Process
  • TABLE 4.2: Common Sources of Somatic Cells for Reprogramming into iPSCs
  • TABLE 4.3: Key Reprogramming Vectors used in iPSC Generation
  • TABLE 4.4: Methods of selecting iPSC Colonies after Reprogramming
  • TABLE 4.5: Examples of Differentiated Cell Types from iPSCs
  • TABLE 4.6: Examples of iPSC-Derived Organoids
  • TABLE 5.1: Landmark Publications in iPSC Research
  • TABLE 5.2: Rapid Growth of iPSC Publications in PubMed.gov
  • TABLE 5.3: Anticipated advancements in iPSC-based therapeutic applications
  • TABLE 5.4: Enhanced Disease Modeling and Drug Discovery
  • TABLE 5.5: Technological Innovations and Automation
  • TABLE 6.1: Number of Patents filed per year, 1993-April 3, 2026
  • TABLE 6.2: iPSC Patent Applications by Jurisdiction as of April 3, 2026
  • TABLE 6.3: Top 100 iPSC Patent Applicants as of April 3, 2026
  • TABLE 6.3: (CONTINUED)
  • TABLE 6.3: (CONTINUED)
  • TABLE 6.4: Top 100 Inventors of iPSC Patent Applications
  • TABLE 6.4: (Continued)
  • TABLE 6.4: (CONTINUED)
  • TABLE 6.5: Top 100 Owners of iPSC Patent Applications
  • TABLE 6.5: (CONTINUED)
  • TABLE 6.5: (CONTINUED)
  • TABLE 6.6: Legal Status of iPSC Patent Applications as of April 4, 2026
  • TABLE 6.7: Recently Granted iPSC Patents (2024-2026)
  • TABLE 6.8: Licensing Fees for iPSC Patents
  • TABLE 7.1: Late-Stage iPSC Clinical Trials & Progress
  • TABLE 7.2: Recruitment Status of iPSC Clinical Trials, 2023-2026
  • TABLE 7.3: Select Clinical Trials in Ocular Diseases
  • TABLE 7.4: Select Clinical Trials Focusing on CNS Disorders
  • TABLE 7.5: Select Clinical Trials Focusing on IPSC-Based Cardiomyocytes and Muscle Products
  • TABLE 7.6: Select Clinical Trials focusing on iPSC-Based in Immune and Blood Products
  • TABLE 7.7: Select Stromal Products in Clinical Trials
  • TABLE 7.8: iPSC-based Clinical Trials by Phase of Study
  • TABLE 7.9: Geographic Distribution of iPSC Clinical Trials
  • TABLE 7.10: Key Future Directions of iPS-Based Trials
  • TABLE 8.1: M&A Deals signed in iPSC Sector, 2023-2026
  • TABLE 8.2: Collaboration/Partnership & Licensing Deals in iPSC Sector, 2023-2026
  • TABLE 8.3: Venture Capital Funding Raised by iPSC Companies, 2021-April 2026
  • TABLE 9.1: Core Reprogramming Factors (OSKM)
  • TABLE 9.2: Top Companies offering iPSC Reprogramming Services
  • TABLE 9.3: Key Combination of Factors for Direct Reprogramming
  • TABLE 9.4: Companies Involved in Direct Reprogramming Services
  • TABLE 9.5: Efficacy of iPSC Reprogramming Methods
  • TABLE 9.6: Companies offering CRISPR/Cas9 Services for iPSC Generation
  • TABLE 9.7: Key Companies developing iPSC-Derived Organoids
  • TABLE 9.8: Key Companies developing iPSC-Derived Cardiac Tissue Sheets
  • TABLE 9.9: Companies developing iPSC-Derived RPE Sheets
  • TABLE 10.1: Key Human iPSC Banks
  • TABLE 10.2: iPSC Lines available with EBiSC
  • TABLE 10.3: Price List for CiRA’s Clinical Grade iPSCs
  • TABLE 10.4: Cell Types Banked by WiCell
  • TABLE 10.5: iPS Cell Lines in Coriell’s Collection
  • TABLE 10.6: Cell Sources & Reprogramming Methods in iPSC Banks
  • TABLE 10.7: Ownership & Funding for iPSC Banks
  • TABLE 11.1: Top Providers of iPSC Research Products for Researchers
  • TABLE 11.2: Commonly used iPSC Reprogramming Kits
  • TABLE 11.3: Commonly used Culture Media and Reagents in Research
  • TABLE 11.4: Key Companies offering iPSC-Derived Cell Types for Research
  • TABLE 11.5: Companies providing iPSC-Derived 3D Organoids for Research
  • TABLE 11.6: Companies offering iPSCs-related Specialized Services
  • TABLE 11.6: (CONTINUED)
  • TABLE 11.7: Key Companies involved in Patient-Specific Disease Modeling
  • TABLE 11.8: Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery
  • TABLE 11.9: Cardiovascular Drugs Tested in iPSC Models
  • TABLE 11.10: Companies offering iPSC-derived Neuronal Cells for Drug Discovery
  • TABLE 11.11: Drugs Tested for Neurological Diseases using iPSCs
  • TABLE 11.12: Companies offering iPSC-Derived RPEs
  • TABLE 11.13: Drugs Tested for Ocular Diseases using iPSC Lines
  • TABLE 11.14: Companies developing iPSCs to Discover Drugs for Metabolic Diseases
  • TABLE 11.15: Drugs Tested in iPSCs for Metabolic Diseases
  • TABLE 11.16: Companies developing iPSCs to Discover Drugs for Blood Disorders
  • TABLE 11.17: Drugs Tested for Blood Disorders using iPSCs
  • TABLE 11.18: Key Companies offering HTS Services using iPSCs
  • TABLE 11.19: Companies offering Toxicity Testing Services using iPSCs
  • TABLE 11.20: Drugs Tested for their Toxicity using iPSC Lines
  • TABLE 11.21: Companies using iPSCs in Personalized Medicine and Genomic Studies
  • TABLE 11.22: Key Applications of iPSC-Derived Cells in Cell Therapy
  • TABLE 11.23: Key Players & Focus Areas in iPSC-Based Cell Therapy
  • TABLE 11.24: Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials
  • TABLE 11.25: Select iPSC-Based Cell Therapy Clinical Trials
  • TABLE 11.26: Major Conservation Initiatives & Species
  • TABLE 11.27: Companies developing Cultured Meat using iPSC-Derived Cells
  • TABLE 12.1: Global Market for iPSCs by Geography, 2025-2034
  • TABLE 12.2: Global Market for iPSCs by Market Segments
  • TABLE 12.3: Global Market for iPSC-Related Reprogramming Technologies, 2026-2034
  • TABLE 13.1: AcceGen’s Pipeline Product Candidates
  • TABLE 13.2: Aspen’s Clinical Pipeline
  • TABLE 13.3: BlueRock’s Pipeline Focusing on New Therapies
  • TABLE 13.4: BrightPath’s Product Pipeline
  • TABLE 13.5: Cartheric’s R&D Pipeline of Allogeneic Products
  • TABLE 13.6: Celregen’s Key iPSC Product Candidates
  • TABLE 13.7: Cellectis’ Main Product Candidates
  • TABLE 13.8: Celregen’s Product Pipeline
  • TABLE 13.9: Century Therapeutics’ Pipeline Overview
  • TABLE 13.10: Cynata’s Clinical Pipeline
  • TABLE 13.11: Factor Bioscience’s iPSC-Based Clinical Trials
  • TABLE 13.12: Fate Therapeutics’ Pipeline Overview
  • TABLE 13.13: Gameto’s Pipeline
  • TABLE 13.14: Greenstone’s Pipeline
  • TABLE 13.15: Healios’ Research and Development Status
  • TABLE 13.16: Hebecell’s Pipelines
  • TABLE 13.17: HELP’s R&D Pipeline
  • TABLE 13.18: Herophilus’ Pipeline Development using Organoids
  • TABLE 13.19: Key Available Organoid Types with HUB
  • TABLE 13.20: iCamuno’s Product Pipeline
  • TABLE 13.21: IPS HEART’s Pipeline
  • TABLE 13.22: iPSirius’ Pipeline
  • TABLE 13.23: iRegene’s Pipelines
  • TABLE 13.24: Kenai’s Pipeline
  • TABLE 13.25: Khloris’ iPSC Product Development Stages and Diseases Addressed
  • TABLE 13.26: Kiji’s R&D Pipeline
  • TABLE 13.27: Laverock’s Pipeline
  • TABLE 13.28: Pipeline from Lineage Cell Therapeutics
  • TABLE 13.29: Megakaryon’s R&D Pipeline
  • TABLE 13.30: Morphocell’s Pipeline
  • TABLE 13.31: ReproCELL’s Clinical Pipelines Currently under Development
  • TABLE 13.32: Ricoh’s Therapeutics Development Pipeline
  • TABLE 13.33: Sana’s Product Candidates
  • TABLE 13.34: Sumitomo’s iPSC Products in Development
  • TABLE 13.35: Vanqua Bio’s Pipeline
  • TABLE 13.36: Vascugen’s Product Pipeline
  • TABLE 13.37: VCCT’s Pipeline